Physician profile

Anna Silverberg

Adult Health (Nurse Practitioner) · Water Mill, NY

NPI 1912330630

$343.47

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$87.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Biotech, INC. $64.99 2021
Astrazeneca Pharmaceuticals LP $60.45 2022-2024 Enhertu, Lynparza
Genzyme Corporation $47.38 2021
Glaxosmithkline, LLC. $45.62 2021
Amgen INC. $28.00 2021
Novartis Pharmaceuticals Corporation $27.16 2024
Alnylam Pharmaceuticals INC. $23.23 2024 Givlaari
Puma Biotechnology, INC. $20.01 2021
Tersera Therapeutics LLC $14.12 2021
Dova Pharmaceuticals $12.51 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Anna Silverberg

$343.47

in general payments reported 2019-2025

Years
2021-2024
Top company
Janssen Biotech, INC.

https://glasscript.com/doctor/10543470/anna-silverberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.